Pregnancy care focus Target prenatal care providers and maternal-fetal medicine specialists with biomarker panels and clinical assay workflows that identify women at risk for preeclampsia, gestational diabetes, preterm birth, and IUGR to enable personalized monitoring and intervention.

Clinical assay readiness Position the company as a partner capable of translating biomarker panels into clinically deployable assays compliant with ISO 13485, appealing to hospital labs, reference labs, and diagnostic developers seeking regulatory-aligned solutions.

Strategic partnerships Leverage past collaboration signals with Preeclampsia Foundation, renegade.bio, and SQU4RE.com to open co-development, pilot, and distribution opportunities with academic centers, biotech ecosystems, and contract research organizations.

Funding and validation Use the documented $9.6M in funding and recent R&D and alliance awards as proof points to engage investors, grant-backed programs, and potential strategic partners evaluating scalable, funded pipeline opportunities.

Lean accelerator fits Target small to mid-sized biotech and diagnostics players seeking niche, high-impact obstetrics biomarker solutions, highlighting the company’s lean team, agility, and potential for rapid co-development and market entry.